Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lapatinib Versus Lapatinib With Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A Randomized Phase II Trial

NCT01145404 is registered in ClinicalTrials.gov with National Center for Tumor Diseases, Heidelberg as lead sponsor.

NCT NCT01145404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01145404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lapatinib Versus Lapatinib With Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A Randomized Phase II Trial
Lead sponsor
National Center for Tumor Diseases, Heidelberg
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2010
Completion date
October 31, 2013
Enrollment
76 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal cancer